Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.
adipocyte
adipose tissue
nonalcoholic fatty liver disease
raltegravir
weight gain
Journal
AIDS patient care and STDs
ISSN: 1557-7449
Titre abrégé: AIDS Patient Care STDS
Pays: United States
ID NLM: 9607225
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
14
10
2021
Statut:
ppublish
Résumé
Integrase inhibitors appear to increase body weight, but paradoxically some data indicate that raltegravir (RAL) may decrease liver fat. Our objective was to study the effects of switching from a protease inhibitor (PI) or efavirenz (EFV) to RAL on liver fat, body composition, and metabolic parameters among people living with HIV (PLWH) with high risk for nonalcoholic fatty liver disease (NAFLD). We randomized overweight PLWH with signs of metabolic syndrome to switch a PI or EFV to RAL (
Identifiants
pubmed: 34524919
doi: 10.1089/apc.2021.0106
doi:
Substances chimiques
Alkynes
0
Benzoxazines
0
Cyclopropanes
0
Protease Inhibitors
0
Raltegravir Potassium
43Y000U234
efavirenz
JE6H2O27P8
Banques de données
ClinicalTrials.gov
['NCT03374358']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM